title: Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung Signature.
abstract: Use of adjuvant chemotherapy remains a complex decision in the treatment of early stage non-small cell lung cancer (NSCLC), with risk of recurrence being the primary indicator (i.e. adjuvant chemotherapy is considered for patients at high risk of recurrence but may not be beneficial for patients at low risk). However, although several clinical and pathological factors are typically considered when assessing the risk of recurrence, none are significantly associated with clinical outcome with the exception of tumor size. GeneFx® Lung (Helomics™ Corporation, Pittsburgh, PA) is a multi-gene RNA expression signature that classifies early stage NSCLC patients as high-risk or low-risk for disease recurrence. GeneFx Lung risk category has been shown to be significantly associated with overall survival in several independent clinical studies. The published literature regarding the analytical validity, clinical validity and clinical utility of GeneFx Lung is summarized herein.
authors.affiliation: Applied Molecular Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
authors.forename: Sandy
authors.initials: S
authors.lastname: Der
authors.affiliation: Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
authors.forename: Chang-Qi
authors.initials: CQ
authors.lastname: Zhu
authors.affiliation: Helomics Corporation, Pittsburgh, PA, United States of America.
authors.forename: Stacey
authors.initials: S
authors.lastname: Brower
authors.affiliation: Helomics Corporation, Pittsburgh, PA, United States of America.
authors.forename: Arlette
authors.initials: A
authors.lastname: Uihlein